Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.
Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would have required a new state board — which is chartered
April 12, 2024